The Technical Analyst
Advaxis, Inc. [ADXS]
Exchange: Other OTC Sector: Healthcare Industry: Biotechnology
Advaxis, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.26% $0.600
/ 19 apr 2024 @ 09:47
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 25.58 mill |
| EPS: | -2.51 |
| P/E: | -0.240 |
| Earnings Date: | May 21, 2024 |
| SharesOutstanding: | 42.63 mill |
| Avg Daily Volume: | 0.0230 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | |||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.240 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.240 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.506 - 0.694 ( +/- 15.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Israel Biotech Fund I, L.p. | Buy | 2 250 000 | Warrants |
| 2024-03-01 | Israel Biotech Fund I, L.p. | Buy | 1 500 000 | Convertible Promissory Note |
| 2024-03-01 | Israel Biotech Fund I, L.p. | Sell | 3 750 000 | Rights |
| 2024-03-01 | Israel Biotech Fund I, L.p. | Buy | 2 250 000 | Warrants |
| 2024-03-01 | Israel Biotech Fund I, L.p. | Buy | 1 500 000 | Convertible Promissory Note |
| INSIDER POWER |
|---|
| 28.64 |
| Last 87 transactions |
| Buy: 80 027 407 | Sell: 40 707 099 |
Forecast:
11:27 - $0.559
Live Trading Signals (every 1 min)
Forecast
1: 09:57 - $0.545
Forecast 2: 10:47 - $0.559
Forecast 3: 11:27 - $0.559
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.600 (5.26% ) |
| Volume | 0.0021 mill |
| Avg. Vol. | 0.0230 mill |
| % of Avg. Vol | 8.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADXS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ADXS
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Latest Press Releases
2024-03-26 08:00:00 - Press Release
Ayala Pharmaceuticals Announces Completion Of Sale Of Al102 To Immunome
Monmouth junction, n.j., march 26, 2024 (globe newswire) -- ayala pharmaceuticals, inc. (otcqx: adxs), a clinical-stage oncology company, today announced the completion of the previously announced sale of al102, and related drug candidate al101, to immunome, inc. (nasdaq: imnm).
2023-10-23 07:00:00 - Press Release
Ayala Pharmaceuticals Presents Updated Al102 Results From Phase 2 Clinical Trial In Desmoid Tumors At Esmo Congress 2023
Al102 1.2 mg once daily treatment achieved overall response rate of 83% in the evaluable population al102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in t2w signal intensity rehovot, israel and monmouth junction, n.j., oct. 23, 2023 (globe newswire) -- ayala pharmaceuticals, inc. (otcqx: adxs), a clinical-stage oncology company, today announced that new data from the ringside study evaluating its lead investigational candidate al102 for the treatment of desmoid tumors (dt) are being presented today at the european society for molecular oncology (esmo) congress 2023, taking place october 20th to 24th in madrid, spain.
2023-10-19 08:00:00 - Press Release
Ayala Pharmaceuticals Announces Closing Of Merger With Biosight
Rehovot, israel & monmouth junction, n.j., oct. 19, 2023 (globe newswire) -- ayala pharmaceuticals, inc. (otcqx: adxs), a clinical-stage oncology company, today announced the closing of its merger with biosight, ltd. (“biosight”), pursuant to which ayala acquired biosight. the combined company will operate under the name ayala pharmaceuticals, inc., and its shares will continue to trade on the otcqx under ayala's current ticker symbol (“adxs”).
2023-08-10 16:30:00 - Press Release
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results And Provides Corporate Update
Successful end-of-phase 2 meeting with fda regarding al102 for the treatment of desmoid tumors enrollment in the phase 3 segment of ringside trial evaluating al102 continuing globally as planned definitive merger agreement with biosight, expected to close near end of q3 2023 rehovot, israel and monmouth junction, n.j., aug. 10, 2023 (globe newswire) -- ayala pharmaceuticals, inc. (otcqx: adxs), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.
2023-08-01 08:00:00 - Press Release
Ayala Pharmaceuticals Announces Abstracts On Al102 And Al101 Accepted For Presentation At Esmo Congress 2023
Rehovot, israel and monmouth junction, n.j., aug. 01, 2023 (globe newswire) -- ayala pharmaceuticals, inc. (otcqx: adxs), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors al102 and al101 at the european society for molecular oncology (esmo) congress 2023, to be held in madrid, spain 20-24 october 2023.
Latest News
2022-05-26 17:00:00 - GlobeNewsWire
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® (pembrolizumab)
2021-11-10 09:26:25 - PennyStocks
3 Hot Penny Stocks That Retail Traders Are Watching Right Now
Why retail traders are watching these penny stocks right now The post 3 Hot Penny Stocks That Retail Traders Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-02 13:22:56 - PennyStocks
Top Penny Stocks to Buy From TikTok? 3 That Investors Are Watching
These penny stocks are popular on TikTok, are they on your watchlist? The post Top Penny Stocks to Buy From TikTok?
2021-11-01 12:18:14 - InvestorPlace
6 of the Hottest Stocks to Pick Up for Less Than $1
These penny stocks are trading for under a dollar, but could change that in the coming months with their strong fundamentals. The post 6 of the Hottest Stocks to Pick Up for Less Than $1 appeared first on InvestorPlace.
2021-10-27 16:49:08 - PennyStocks
Best Penny Stocks to Buy Next Month? 3 You Need to Know About
Which penny stocks are on your November watchlist? The post Best Penny Stocks to Buy Next Month?
2021-10-26 09:15:17 - PennyStocks
Top Trending Penny Stocks to Watch Next Month
With so many trending penny stocks to buy, which small caps are you watching? The post Top Trending Penny Stocks to Watch Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-10-12 16:49:01 - PennyStocks
3 Trending Penny Stocks For Your Small-Caps Watchlist Right Now
These trending penny stocks could be worth adding to your October watchlist, here's why The post 3 Trending Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-10-08 16:18:53 - PennyStocks
Top Biotech Penny Stocks to Watch With High Volume Right Now
Are these high volume biotech penny stocks worth adding to your watchlist right now? The post Top Biotech Penny Stocks to Watch With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-20 10:11:03 - PennyStocks
3 Tech Penny Stocks to Watch During the Market Crash
Can tech penny stocks perform well amidst today's stock market crash? The post 3 Tech Penny Stocks to Watch During the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-10 15:27:59 - PennyStocks
Hot Penny Stocks to Add to Your September Watchlist
Why investors are watching these 3 penny stocks right now The post Hot Penny Stocks to Add to Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.